Legend Biotech Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Legend Biotech de 63.7% y 36.4% por año respectivamente. Se prevé que el BPA crezca en un 69.4% al año. Se espera que la rentabilidad financiera sea de 28.1% en 3 años.

Información clave

63.7%

Tasa de crecimiento de los beneficios

69.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.6%
Tasa de crecimiento de los ingresos	36.5%
Rentabilidad financiera futura	30.3%
Cobertura de analistas	Good
Última actualización	21 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Recent updates

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30

Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)

Nov 22

Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?

Aug 26

Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%

Jun 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:LEGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,561	154	156	181	14
12/31/2025	1,027	-153	-154	-197	19
12/31/2024	545	-323	-408	-163	19
3/31/2024	343	-466	-264	-239	N/A
12/31/2023	285	-518	-416	-393	N/A
9/30/2023	233	-509	-371	-347	N/A
6/30/2023	165	-532	-378	-359	N/A
3/31/2023	112	-517	-276	-262	N/A
12/31/2022	117	-446	-224	-201	N/A
9/30/2022	106	-416	-237	-221	N/A
6/30/2022	96	-457	-221	-194	N/A
3/31/2022	119	-346	-293	-250	N/A
12/31/2021	69	-404	-244	-198	N/A
9/30/2021	93	-356	-245	-185	N/A
6/30/2021	89	-297	-259	-205	N/A
3/31/2021	80	-340	-256	-204	N/A
12/31/2020	75	-266	-253	-223	N/A
9/30/2020	59	-310	-300	-227	N/A
6/30/2020	64	-271	-209	-143	N/A
3/31/2020	61	-165	-160	-125	N/A
1/1/2020	62	-102	-110	-83	N/A
12/31/2018	49	-3	287	308	N/A
12/31/2017	24	9	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que LEGN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que LEGN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que LEGN sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (36.4% al año) de LEGN crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (36.4% al año) de LEGN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LEGN sea alta dentro de 3 años (28.1%)

Legend Biotech Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 11%

Price target increased by 7.7% to US$79.70

Consensus forecasts updated

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Consensus estimates of losses per share improve by 32%

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Recent updates

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Legend Biotech stock slides on proposed ADS offering

Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901

Legend Biotech ends Phase 1 trial for lymphoma candidate

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 32%

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

High number of new and inexperienced directors

Legend Biotech Announces Executive Changes